0001564590-22-016244.txt : 20220428 0001564590-22-016244.hdr.sgml : 20220428 20220428083042 ACCESSION NUMBER: 0001564590-22-016244 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220427 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20220428 DATE AS OF CHANGE: 20220428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evoke Pharma Inc CENTRAL INDEX KEY: 0001403708 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208447886 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36075 FILM NUMBER: 22862424 BUSINESS ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 BUSINESS PHONE: 858-345-1494 MAIL ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 8-K 1 evok-8k_20220427.htm 8-K evok-8k_20220427.htm
false 0001403708 0001403708 2022-04-27 2022-04-27

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  April 27, 2022

 

EVOKE PHARMA, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

 

001-36075

 

20-8447886

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

420 Stevens Avenue, Suite 370

Solana Beach, California

 

92075

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (858) 345-1494

(Former Name or Former Address, if Changed Since Last Report.)

 

Securities registered pursuant to Section 12(b) of the Exchange Act

 

 

 

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock,
par value $0.0001 per share

EVOK

The Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

US-DOCS\131563908.3

 


 

 

Item 5.07Submission of Matters to a Vote of Security Holders.

 

Results of Annual Meeting of Stockholders

 

Evoke Pharma, Inc. (the “Company” or “our”) held its annual meeting of stockholders (the “Annual Meeting”) solely by means of remote communication through a live webcast on April 27, 2022, at 8:30 a.m., Pacific Time. As of the close of business on February 28, 2022, the record date for the Annual Meeting, there were 32,917,901 shares of common stock entitled to vote, of which there were 24,934,254 shares present at the Annual Meeting in person or by proxy. At the Annual Meeting, stockholders voted on four matters: (i) the election of two Class III Directors for a term of three years expiring at the 2025 Annual Meeting of Stockholders, (ii) the ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022, (iii) the approval of, on an advisory basis, the compensation of our named executive officers, and (iv) to grant to the board of directors the authority to effect a reverse stock split of our outstanding common stock by amending our Amended and Restated Certificate of Incorporation within one year and within a range of not less than one-for-five and not more than one-for-twenty, if the board deems it within the company’s best interests (the “Reverse Stock Split Proposal”). The results of the voting were as follows:

 

Election of two Class III Directors for a term of three years expiring at the 2025 Annual Meeting of Stockholders

 

Malcolm R. Hill, Pharm. D.

  For

  13,848,665

      Withheld

    5,017,695

Vickie W. Reed

  For

  14,578,385

      Withheld

    4,287,975

 

There were 6,067,894 broker non-votes related to each of the two director nominees for election.

 

The two nominees for Class III Director were elected.

 

Ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022

 

 

Shares Voted                             For      19,944,368       Against         2,673,179       Abstain      2,316,706

 

There were no broker non-votes related to the appointment of BDO USA, LLP.

 

The appointment of BDO USA, LLP was ratified.

 

The approval of, on an advisory basis, the compensation of the Company’s named executive officers

 

Shares Voted                             For      11,455,342      Against         5,521,311     Abstain       1,889,706

 

 

There were 6,067,894 broker non-votes related to the compensation of our named executive officers.

 

The foregoing proposal was approved.

 

The grant to the board of directors for the authority to effect a reverse stock split of our outstanding common stock by amending our Amended and Restated Certificate of Incorporation within one year and within a range of not less than one-for-five and not more than one-for-twenty, if the board deems it within the company’s best interests.

 

 

Shares Voted                         For     16,707,172Against     6,816,248     Abstain       1,410,834

 

There were no broker non-votes related to the amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock.

 

US-DOCS\131563908.3

 


 

 

The foregoing proposal was approved.  The Company’s board of directors is authorized for one year from the Annual Meeting to effect the reverse stock split authorized by this proposal.

 

Reverse Stock Split

 

Pursuant to the authority granted by the Company’s stockholders’ approval of the Reverse Stock Split Proposal, on April 27, 2022, the Company’s board of directors determined to effect the reverse stock split of the shares of the Company’s common stock and approved a specific ratio of 1-for-12 (the “Reverse Stock Split”) and authorized the filing of a Certificate of Amendment to the Charter to effect the Reverse Stock Split. The Reverse Stock Split will not reduce the total number of shares of common stock that the Company is authorized to issue, which will remain 50,000,000 shares.  The Reverse Stock Split will be effective as of the opening of trading on The Nasdaq Capital Market on May 23, 2022.

 

Forward-Looking Statements

 

Statements in this current report on Form 8-K that are not statements of historical fact are forward-looking statements, which involve a number of risks and uncertainties. Such statements include statements about the Reverse Stock Split and the timing thereof and can be identified by using the words “will”, “plans” and “expects”. For such statements, the Company claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from our expectations. Factors that could cause actual results to differ materially from the forward-looking statements include potential delays in effecting the Reverse Stock Split and legal and regulatory developments. These forward-looking statements represent our judgment as of the time of this current report on Form 8-K. The Company disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

 

 

 


US-DOCS\131563908.3

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

EVOKE PHARMA, INC.

 

 

 

 

Date: April 28, 2022

 

 

 

By:

 

/s/ Matthew J. D’Onofrio

 

 

 

 

Name:

 

Matthew J. D’Onofrio

 

 

 

 

Title:

 

Executive Vice President,
Chief Business Officer and Secretary

 

US-DOCS\131563908.3

 

EX-101.SCH 2 evok-20220427.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 evok-20220427_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 4 evok-20220427_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 27, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 27, 2022
Entity Registrant Name EVOKE PHARMA, INC.
Entity Central Index Key 0001403708
Entity Emerging Growth Company false
Entity File Number 001-36075
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-8447886
Entity Address, Address Line One 420 Stevens Avenue
Entity Address, Address Line Two Suite 370
Entity Address, City or Town Solana Beach
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92075
City Area Code (858)
Local Phone Number 345-1494
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock,par value $0.0001 per share
Trading Symbol EVOK
Security Exchange Name NASDAQ
XML 6 evok-8k_20220427_htm.xml IDEA: XBRL DOCUMENT 0001403708 2022-04-27 2022-04-27 false 0001403708 8-K 2022-04-27 EVOKE PHARMA, INC. DE 001-36075 20-8447886 420 Stevens Avenue Suite 370 Solana Beach CA 92075 (858) 345-1494 Common Stock,par value $0.0001 per share EVOK NASDAQ false false false false false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports evok-8k_20220427.htm evok-20220427.xsd evok-20220427_lab.xml evok-20220427_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "evok-8k_20220427.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "evok-8k_20220427.htm" ] }, "labelLink": { "local": [ "evok-20220427_lab.xml" ] }, "presentationLink": { "local": [ "evok-20220427_pre.xml" ] }, "schema": { "local": [ "evok-20220427.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "evok", "nsuri": "http://www.evokepharma.com/20220427", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "evok-8k_20220427.htm", "contextRef": "C_0001403708_20220427_20220427", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "evok-8k_20220427.htm", "contextRef": "C_0001403708_20220427_20220427", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.evokepharma.com/20220427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001564590-22-016244-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-016244-xbrl.zip M4$L#!!0 ( -%#G%2E8WF^O 0 '86 1 979O:RTR,#(R,#0R-RYX MA\9W]Y_0+5'T"<94$I;(3,";AX]OT9<_IQ/T0):PPFB< MD&P%7"$/+95*1T'P_/SLQW/*9<(RI4U)GR2K 'F>4_R7 &P(:(P5(/L;H2B, M(B_L>]'@,>J->OU1&/G#7CBX&%S^'H:C,"PI^#?W 95^(W3AAW[7'_0')<;/ MF'S#"T#WXQ)C? DS/.Q%E[/^H!]C,NOBX:R'PX&V-IL/AF6D2;H1=+%4Z UY M:R%J?SD'QF"#[BC'G%#,T(/S]!VZY\1'MXRAJ1&3: H2Q!/$_E;K6L8CF9^< MC@:7HQCH=6=[!'DQ!+J6KQU2'FVBNJ41J'&JH!+.F/@&380-D6E%YDR*_R& M4&.18TIDO5F ](E%BML.X8IM[ ? M#9Q K,1>>E9G#[L;?/DXR3MH1[<%A&QCH*LT$0KE M_6&2$)N")P)FOCR7%9[9\KJ1SCY?*^L@7HOY6$H%+X3ADJ<5C%WFM8;AVH*Q M?W',*_^L[YR([6OOOPS,=)2/6=HRV$0S%/6Q7YP>A='^WJTLF1( % M$0D#?5L2]6&=,LRQ2FP^AD/3)[I_G-LGAA5='NR4W>GOEV"T2CDL]#P:MP)6 M5O *0-1+0#3J:$=&DGQY?J:4AYF6QMT(:!;G&]X-C@W-'HR* 3 E[:"[&^.. M03@Z9[X>"!-,V1!*+O23 -G6U130X9NA;7:XQXI=-K=:!4L!\^N.B:CGPOB5X9FOX^98 M#@Q4@V>#KD6 37;PG*RBR@A/#-E&2;Y#F!6J309?=Z0N'U:\9_YW=W4J-'5W M/WOJO?Y,)LQ!P 5DP !4 !E=F]K+3(P,C(P-#(W7VQA M8BYX;6S-7%MSVC@8?=^9_0]:^M+.UAA,NA2F22=+DAUFTR03Z&YG=W8ZPA9$ M4V%1R23P[U?R)<$@&U]$45Y"'.F/JSD!CXAQ3/W31KO9:@#D MN]3#_NRTL>06Y"[&#< #Z'N04!^=-M:(-SZ>_?S3AU\L"UQ<#6_ N1O@1W2! MN4LH7S+T>O3I#?CR^_TUN,;^MPGD"%Q0=SE'?@ L\! $B[YM/ST]-;TI]CDE MRT"P\Z9+YS:PK 1ZP!"4OP 7,$ @_.H#I^4X5NO$QWG M_>2D>^)!=]*&O4D'MKJ";3+M]C8KI8LUP[.' +QVWX0EBO/U?40(6H,K[$/? MQ9" 47*F;\'0=YO@G!!P+Z=Q<(\X8H_(:\:H1.C6)XEXPB.?AS^>-C;46TT8 M:5(VLYU6JV,GHQOQ\-7.^*=..+K=Z_7L\+?/0SE6#12P;?O+I^N1^X#FT!)6 MB12XDH#C/@\/7E,W]*A 72!SA/S)2H99\I#5=JQ.N[GB7D.H 4"D!Z,$W:,I MD-\_WP\S.7NV'&'[:":"XUW#"2*BYA#B@:&I>AYA+#5-UM&3=;1_DW6\4J$% MZX7H!X[G"R)4L6N7>H,"O=5N ^HN^ XQ3+U+7[/(:MC#%#\*(-.L>A:P[A,8 MB^L;TEOZ+J3VHFD B>:B=R U%ETA&\%NG76#,(5\$M*()7D&X2*B(A+4ABO, M+] 4+DFP6R87D\,:=Q#$,M6V$0FX/"+AN"4/6:UV?.E]I0#.KCRL12[W\4B) MF+,J1/5':] &,EH%R/=0?-E_QJ9N]HEQY#9G]-'V$ [/Z?N)?&E%+\/S$#]^ MO?0#'*P'8@?"(!D*BM6?:)WF)G(MHRPY&)[0:2-GLITN4HZ7"ZIX)3=/R+<^ MCXJ"?263K70PQ.F2A:MM83V#E^X]BVA S -"(B"8/M@O!>W6?\[<5!60N4D! MXN6>&N(1MDO%+F$16&0S\U-&Y[EJQK1TKTJV[FP,J-@ GT^XH'*#HIG8FE0M M"RD0/1F(1#\+D<&_"?9_Q[==K3+-%$*[S9+HB<%8TBUN3JFF7 M&?QF=X(/&/'T>U MT#13"V-$)>7TU'=U?+[WDD]=REXFMR;7:^\4V $OG!$/$$3ADZ;CAS;?"KI7 M)>-DW[Z\%E9FZ=77\:ZV";_A<:('F.G^A<%^@^ MA4Q3G%07^[CWA^G"2]P:ZNK#RSEB,^S/_F#T*7@8T/D"^B7OPC,@ZF1$"7FP MYDS80$0'8CY3FC3?(EI0-T/M(/6Z#J M")X+?;"4IUC?@I 74 9B;B#)38E_,1]I25$-]XQDVQ6[5(JC/YQ7608R0>J8D0%ZL-81?"!-:-ARL<\J6E@]8VTA=1W1U1;GGB?JY_&W M:^RC=KF64 +4T5T!>+!6B$G>)B_DNZ80N/6-63KR[*&%5#/2"J)R(65"^QC1 M=^I&W]&MM_.#HS]^HN9&WRD:?><0T==DQ?[H.S\L^@/Q\I:-Z9-?*?B;TS5H M_0)W^-!++GF[(-D,"[S"%%7G/,DK5 DKQ3#5%W0R1';=%[-#<$7>4!Y#\@Q?E M'R:I$30(GT(\?"]$=$#P&?6X*-<@51\H9#/3#'4/%+9!P_L-Y>DQ!,MD/CVG MXKL--S#TYSI<426\(3%6JDRSE#!%45).S/IAE)_@(7=4DW,;1 M'\R0 804QCQBS%2=YJEBDL*DO+CUP_HWPT& _ &=SY=^_)"2%TULQN1JHBK! M]&*\@(,0_9"!'3,H_Q'. M:#V?T,+;\JU)U31,@1P@IQ$\B/"/'T^UT#13"V-$)>7TU'<-O5RY#^)D49G/ M,ZGGUFOR3:P#W#3&+""A,>3S3+DNT'T*F:8X*27VYH%K\4K^NZKX$([^A=/9 M_U!+ P04 " #10YQ4\?'4V D% " +0 %0 &5V;VLM,C R,C T,C=? M<')E+GAM;.5:6X_B-A1^K]3_X*8ONVISA1$#6G9%YU*A,C,(:+OJR\HD!JQQ M[-0.MW_?XT (#,D.[)!5I?! ;N?R^?/).;;C#Y]6(4,+(A45O&VXEF,@PGT1 M4#YM&W-E8N53:B 58QY@)CAI&VNBC$\??_SAPT^FB6[ONX^HX\=T06ZI\IE0 M#1_>H\^_#7JH1_GS&"N";H4_#PF/D8EF<1RU;'NY7%K!A'(EV#P&[\KR M16@CTTQ-WTB"]0-TBV."DE\+>8[GF4[=]!HCK]:JU5N.9S5K3N.J-YCY2$:TEG;; M;\44XY7@(EQOP*6O1GKL\.".QS1>=_E$@*[F]S70 S#TY1Q#Q2V*),0BCQ-I MS<&! EG%A &.))8I][A M.AP+=BJV%TH7!Y6VW?7&(QJSLSG+]"X.K2_)C0@A@GRBPZBKU)S(D0Y1^329 M$'DJU-?ME W][:#+A0O%B_HTACA[@.0HH9Z=' 8YFA>']S<$&J0FS<>-T$]-/#=P+IO!>N6!G:$5]T 2@B=;+/?>?GI%2,E@88Y ME)"1D(FOY&6Y$7,>R_7Y*>(54R4UX)ZR,PO!L5Y)T.Y"(J=0L7^78AG/H#!& MF*_/0UE@HB3 -Q!X$K,N#(%6?Y SH1XIEP1R0*94@2<>GS/UR->].,1T*M:' M(9J V5B@EUU.Q5B@?'&0'7 2:$?W#$]/!?="J33F1H#C7,(V.I4[983)E*$ MN5BVWD0>>4+"M*=MN([C.I;C&"B"&-3SSK8!Y7VN (R(-&P]\8!FP/Q(DJ"W M:7$WGHR.BB;@XR]Q.TIJ M%N;4#***II_C[<4[2BI5S3_ MOMC]E?%1U;R;NU,OH^4[9-X/]A$K,$M[UAM[-T_TG][L^O$_4$L#!!0 ( M -%#G%0K%7&9P!@ /GD 4 979O:RTX:U\R,#(R,#0R-RYH=&WM/?US MFTB6/]]5W?_0Y]G9=>H0 O0M.]ER;"?1)K%=EC,S=7556RUH6:P1, U8UO[U M]UX#$DA(0K)LR0I3NTD$_?F^W^O7C]._/PTM0AX9]TS'?G^DRLH18;;N&*9] M__XH\/NEYM'?/_S7?Y[^=ZE$+CYUKLB9[IN/[,+T=,OQ LZ.N]_?D8YMF38C M?WR\_48N'#T8,MLG)3+P?;==+H]&(]GHF[;G6($/\WBR[@S+I%2*!S[GC.(+ M:=H[0K\3Y6KU8:FUM7_492VHB0&^"W< $G\UR8U M69%5N5%M)!K>4/V!WC/2N4@T-)JL1UL5K=FK-JH&U7LJ;?4J5&E4E$:OWV@E M5^JX8V[>#WQRK+\32X3]VC:S+#8FGTR;VKI)+=*-=RH!:'29G%D6N<5N'KEE M'N./S)"C40<^8 "P8'OMIQZWS/='":CA$]GA]V5-42IE@* /$["C1'MCVB'9 MN%X.7\9-V:/SD!H9'S!W0/F0"FS@5I2JUH@[!%[)'[O,FW3J4Z\G1H_?8!>U MI*BEBIKH=$^IF]D'7V1T\7R7IW?@,5V^=Q[+^$9TF#3E_J(U35YES<#]S Y9 M34U]P5I,/;44FYJZE]U4O$HU9D_Z(+LMODDU-7P^L\44%<#K,K[&/@HN/=&3 MF=ESP LQQ9_5N*D>< X\/LYN'[]-K4MW MOGBWJ$+]-[MH.AED69F@*[]IGM MF3V+E; 9XX+WO9*&PB>B;! G:7H=5<0 :JO5*HNW$YKS^4*6:97A;=QP;L@T M<^'K'O4FS&5Z3E53&\O8,6PQ6;-G9JT8FJKE/[Y_Z^H#-J2E61XVGQ;-H"+# MHUA%J3HA/! VP7 %=4"CD@"LJ4_ZK>Z4[F ^^=D=IFLJ^YS:7M\!$8((Q"77 M2HI6TNJ)04I ):F!8JI9-4YSRI>+"0&%YY&0HHP:^/>0^52HG1+[,S ?WQ^= M.S90FU^Z@ST>$3W\]?[(!R(LB]ZDC/U\T[<8_ /%8JGY\,]8',K0!EZ7X_>G MY7@FU 97GT$AV* ]?<;)(^H;36ZHD6#O.<;XPZEA/A+/'UOL_9%A>JY%QXA# MAHO^CU/SJ8W#,8Z_PI^F83!;_!2_H>U5B!AB&N^//OU3P?\ ,#8=XI#,;)^! MLC50X7ZRZ'VTQ2?_EO5A\]A/UUC!]F[40\2P!%%P79WV&(HIYT5J1==N>X"^8D@CQ MT$:B?G_DF4/70F83SP8<5R1P/$'PDV?$KRG7N8.8RBTDUI!3><7/A]-R>C]3 M.,QL/(2%YP1\"@IA0K0C^ NTK8*_Z!=W9 *?T;/XH6G@X[X)-"X6Q3+Y^;SS M-8W,V<[Q3.6,J:*97,"[8\Q,#_*2^V@8?IA8A(UXD.F[=!_@B 4]XC?IQ20G MCI]%0$R"/P'KD#!CYCTM Y_CWV[,[$/*[TV[U'-\WQFV%=<_B9[XCBM^XMB@ M#1 \;>77DS[,5NK3H6F-VW?FD'GDBHW(K3.D=OC.,__-VJH*/8\^_/47M:Z< MG);=U)1B1&J9]W9;AU$9/^DY'-8GI@2+U#2((C=JKD]^$9RLG+C40$-_LJ:- M%BT65H67*[BSKCT^(D8?:(,A)P,6SU2;E*8DD0-GP$!!&!R MV^I!;CNQ_FKF!K-V%*VSYUA&DN2:>?:XZ89^7'7N+B](]^[L[K)+++4@E:4'&T:*$?9[3<&R6OLY:C 7) M[3')Y=*5FVX(A.WMY=4=N;V\N;Z]6Y\.GK6S%Q6M-P'W GA$?(=TF8X>HA85@$O6%? MM\QUN$^.X]^,@AO"/)^P1PRG<_&:&>_:(?XC'EXH9K4L,7LC')W+T E:2]Z2 M,$#S_LA\\ML&]!Y"WX%!QV-8)[.//IRYW+2(UI!$6'Q6-!>2>6\EL_:BDGDQ M@5;F(TFW[-[T<%S_"MZL9P]<_G;]]9+; 5&:F\)%B/ M+Y\HB$,$4R@[8L 1ZI&NRW2,N1C$M(GI>^1\0#%&^:XPD)[%AIL'"G:Z_B@V MY=.>Q4B(P/='8(7KS+(\E^KBK#?Z'>%1_$[MNDT#WXG1KSN615V/M>-_G)"1 M:?@#('K8MHC(^R(NYAOD49#7^Z,0:I-1P_:52M3\.3R9)"O\G48#/EC"IB_J M"2T6?HUYX=>Q=8>#CA>G(%T?5.QY>+)V[AB;ZVH\@,$XJ<]<[CSBG*BL+YA% M1Z"WL]3T:=DW\N!.G45=4E9H>>)J.1&7'T\OPD%YX?'3TG)]GI8_F1:#ECW& MUST-4DN5NM*H%82Y1<+4?E+";,X3YAU]ZD1'4KH0M)M0J::4FM5JH]FL+R/3 MO6>8(I:Q!9-\?S<.AGE*J;\KI%@N M*?;S<.I!$Y6A"'4/3,#"_*44@]<8L@6R5/3"6L8!H)TO45BQQCJ%? M985Y()HI?^8A>E"$N-B";LU;T&>&P9GG17]] T&LKF<]5S6%='T\U/#(&?P9 MS$4AI,6GQZJ29T7:>BOJ!B;8I_!VXU.+@\*ZJBZ$\3G\\YK?.2-[30@[%K4I M^ QU.S&PZBPW2I12Z?F![@Q39R MW0>#C'F%>U*X)]GT [Q*D%FS;/6R.&/[,)\._K+I*2]ZTCP]6O[K+TU-;9QX MQ&<6+ E6JMI%9;U>?G(>XO^H\_P;\8CS(-.(E^1E(4 M,-_'[ +[GAFDBX88^48]/\IEDM=(.(BV7D_+@NVD(+RUA(/='MBGI7D57R<$ M?^JM5I,KM64-JHI<3S58(ZAQN#HDD=S(A71E'-C'G<_T)*IVW!/IG9@3F4R$ MS'O0M ,@Y@L5%8OOQ$!W>!TWS)'5!T2WJ.?M%^9>"PZ<"J/+&P]A MVI\2!'$&I* $%DM($)VC@0E/IO(U-]L)NUI<2 Z0_"J*6NRQT7WOOHZCR1 M'K.<$7J5^!*=3=(L?25]TT(]9WK$Q H>!IC+8"5[YC"P?&HS)_"L,?&H;WK] ML>@9=7!Z0+;A\6ID1/-IIGP XW!"[7'\K@_.D3/"?G@68&(ZAD>.3]%!B4&< MV#4BR=1A,QX#.8:-/I#/S&8<<->Q88X@M.'/9$T.M_6N3:8>7CQBR%C(*9$? MMJ'7]XS4[/D@GB97ZK^>@ KU60GG1AR/.'4S#VT7T]MB NNR>X>1'QT2"K/M M2]1YI.UD&0O#4*FDV=]!R !9H^X,["@?P'N>H.DYCM6C0,\^;5!/D0OC7X)3'UMQF1]+?9"%ANG,_*MJ,/$?@!WDGXIQSRVP"8LJK5 M(J$QJPUR_NF6:!5%AH88^DK#5HCO.>%=2(*?71*DKH)@.%,'HK+O MOX-&A$'6L_,*,? ,,3"%/1E&P)^7 6J5EE0M(092UY,G0J"JR&'+0@X4? ,>0 X*.D))*RT#]2J41(!^US2 M(6Q;R(="/N23#ZTE\J'C>0'CA91X$U*BPDI5+!^=1TI$;?-*B3<8"NK8!L(* M!-B8Z"(L!(M](*,!$Y?%9F(VID< 30!HW,\]N>?.R!\@R%V,XU"/&*QOVF'E M@]!G4VIQ>&?&80M+R53(,9ZJ-4Z$WQ8WAFD (ZZHF>#P"&]:KZ1EC)59GR8> M%'$X[9<85EY07. -8.QR ?3G66B!S%R6<5Z;3Y6,Y_LLICL/9WME ?"RNR!01S["<*@)=S&6- ML.C'QC4[GU^[=>&ZWD#54G4F[TO-@DB^6JY[#H:-R&M!DDAU M"<$E@9N=DKP04*]]0/>C6[JX/N_^GUI1:_5*2VG*E:U ;:/RR@,>S^G2>U;J M<48?2K0/]-JFUHB.O:B"_"XK/[^5*7>1O]KQV1 _!=.85PAIDDT>6==JH4\0 M:H1NT(LN9Z.J^4Y]0+Z':HB2WYRP5E]\4$R^P-[@[9QUEY!V_PH\W^R/5Q^B M)T%8E2O;+A+^S'6D#D'7Q68:]&MEHWN!Y8O;&V>V'> Q.6/"9$ L8-+)(,3 M[,93VF3CJM][ _Q-0?T\PQ\_&D1NQ%>#HB\;':/EA1<#-.4DLLS%+_4$;;SH MA1/PZ.$[,F"6(6K2T1!]PRGZO 3Z4@.G,3T9RG,L9HW1>!TR6#X.P=D0.3+E M@H-QR)W@'HQ/8N$-GQ'KZ9BCCD?SJ9J5$J$^:;8K"J'R4);P8U%X.YL@6&5R MYL6&)G[Y2G!]+_" JO ND4T^L1X/*!\3K1F/%AK1.I@M! MF"GL8GZ6W(]IQ M7!;\4=&DEMJ06HH:YD>).?4PI4J A^"5<=\*\Q\>8:\2M@ASW1+C:%4)O%!) MJU7C<5SX Z,3L,7Y-:"W#$:[AQ*.(T#!ZGX:PYZS&DMI1.$B#(1 ']",!R+]( !%[1L]@26%^9U_XH18RGP]>'S8N >1+?00#=L#70X>S M]&M_!$@<2[&+&P+#8&P(6/;C26)H)VF@AX5X,?<(V,A/2Z?;"$B""$E7 .F& M.Z[C42N653(A=T(:3+07#@"L(SQCY%CJ1>E'7GN9ZLK^G,-+::Y]/W2HR$UM M]:%#0NV*]:^$7RZ]"0MW>/L7<U&4.I=Z-U +">8* M)_Q(]8=[4(JV44IN8R=;$BQ2/UGS,.'E7DN R<+L!,)A8G#DIJA*A; M%"8"H^VU%?":)Q4IPSS79>FW*=Y(ZC*B7&F"X(JNV.$M.LR)7G(/3]64L-&2 MRWB:O+Q!O;&B0:VYHD&C/M-@P < V\3GW&H;)KQ]\5D\^CLM3-8DUN-'_=6Z"I%:E9;4KU>NW%B.YP*(RD?OP.#@(&, JB6Q>. MR3]KDJ(VI'HK17\+-8DJ-PM-,@?;WTS]P63D=QE\:O9<>CQ4(!6JXKFJHBK5 M&DVITBQ4Q7HB+OEGH32V =&JI#4;4JN1I33R^9;9N3J[/RE-^X6*NJ0JS:MC MXVYZI%"7E'I#:K:JI,>=!\:AD5W"X#\6,;%$5!=#QW@-/PIO8K0ACC)#ZR$@ M@X6QAOA08.Z8-(FP6H&O3? EP)Z"]GS$)\1HE-&U% FOS#4["#BWFG*CB#@7 M$>GVMG&RU?D^J-BJ0V6M&J &? QJQ>R>J%RKR_86K$9H#/[VKT6K*-:UP-@IGHW VMNELK+K-%1^$ M%#>ZUKG1):]_-%1M[H.X*LZ&"@=TGQS--7PE/*UH2&IC7>]RE0^9>P5UJ0F+ MT*K-'?F*5561FI7JS^4KOG6K?YTS(%24XD0B>C ;[5M?D^;4Y4G]O=0-V>U! M8%&-J*A&5$02()G!F!'A8R]1W\Z%;X06M1C2J[_I(_B"HA1$";D;.P*!-K M<4M1328Q$V=#\!Y(39$41?P_&GQ.K"]<:X]%>Q7!D GB')?9$=S\Z%.0L% < M*?RVV,RWQ/#E=SHF6B4DL44UB/=*=6=-N8M"@N#SCH#W2M\ER MKM3<#J#XU@7O%)A$A.NP4'; >9CZC9\2%R76G.AK<(('J?#!?.)-NP(;0$\0 MBB \+-*G>MBJ'V'.BC W[1%SJ6D_.A9R5H+_N>D]>$)6!;8.(@DX&,M]RZ0; M0 \ON6#="@R6?$1[3K!0+(DQA<0QA\+J0I\2)1\\UJF-O&XB4D2Z&BHLZ>0&S[\1L904F\]#Y2^@:_J6L. MP[Q\$/U^HH0,/+GAYB-*YT01]&_P5_2AO5N&Z)Y60V_59/R!AB8 0^")3RIA M#4$<&29^L6#RS1UK'!JHZ,>&ZPXKZ<.J:5RPC&*9_ !C2 (]^+(@RDK\1)A;AU6+W6,D:_@4&?6!1'W. #&AL M.:Z80R@E;^DJ@.*C8GT(@G\%QKU0?U.Q#X3#I@7E%_))J/]BC!JF%R%5:"W\ MC**/F$A\(A'+>KNB5*&_8HU@KT35^3'7*41C#RV./P,3+VE$GU9T 2ZZ.%ZT MZ&AO'80M>8^[E>!;7T7FIU[5U:M(GUGM4*>L.(O[)/[#=N(CQ:MK_1>!J@,+ M5&U"[/M)W7-&\>S!<;?S^>KL[L?M97Z:&(9YOAJ M2URR-_7="R, XT&8&4:H<"-%"]. QO, 8F'Y6ZQIW&,#:O7C((%0@E$#M/$" M&PT3'&[J,,ID*SRZRUH-TPRCYV03A9MLBS/MK5YBJ,6WNP^JY$B^8B(1N%X4 M *^MYI;N/R-/H\#^P6,?Y ,JM?='E:-E@N"P*.'RM^NOE^3FR]GM]S.)=*[. M4S4D%Q?F=.>+J0U-P[#8*\M-+2NK: :?VM'R-;XP-CH69. M=_AAU$([KK'_0U.0EY.Z)[^9.N8I,D^D4DIACL_YP&1]\C'^:N]U6!M%9.MU MF I^6>8XP%*@?^T()__#]02P$"% ,4 " #1 M0YQ4I6-YOKP$ !V%@ $0 @ $ 979O:RTR,#(R,#0R M-RYX&UL4$L! A0#% @ T4.<5/'Q MU-@)!0 @"T !4 ( !3PP &5V;VLM,C R,C T,C=?<')E M+GAM;%!+ 0(4 Q0 ( -%#G%0K%7&9P!@ /GD 4 " M 8L1 !E=F]K+3AK7S(P,C(P-#(W+FAT;5!+!08 ! $